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The paper provides a high-level overview of the use of polymeric micelles, polyion complexes, cell 
mediated drug carriers and exosomes in the therapy of cancer and neurodegenerative diseases. The 
author tries to combine the lessons-learned during over a quarter of century work in the field of 
nanomedicine and drug delivery along with a vision statement of some trends and future prospective 
in this field. Several most recent examples from the University of North Carolina and Moscow State 
University laboratories are presented including high capacity polymeric micelles for single and multiple 
water-insoluble drugs for cancer therapy. The nanoscale size polyion complexes formed by ionic block 
copolymers and polypeptides for the delivery of these polypeptides are also discussed. Examples include 
antioxidant enzymes (e.g. superoxide dismutase, catalase), stoichiometric and catalytic scavengers of 
organophosphorus toxins (butirylcholine esterase, organophosphate hydrolase) and neurotrophins 
(brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor). The applications 
include treatments of obesity, stroke, Parkinson’s disease, RETT syndrome, organophosphorus toxins 
poisoning, and some other medical conditions that have been demonstrated using animal models. The 
application of these complexes in the context of the macrophage carriers for drug delivery to the site 
of inflammation is presented. A concept of the use of genetically modified macrophages as natural 
gene delivery vectors is stated and illustrated using Parkinson’s disease therapy as an example. The 
role of exosomes in gene and protein delivery and its potential as a true pharmaceutical modality are 
also discussed.
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Московский государственный университет им. М.В. Ломоносова 
Россия, 119991, Москва, Ленинские горы, 1
В работе представлен обзор по использованию полимерных мицелл, полиионных комплексов, 
опосредуемых клетками носителей и экзосом в терапии рака и нейродегенеративных заболеваний. 
В обзоре рассмотрены основные разработанные в последние десятилетия подходы в области 
наномедицины и доставки лекарств, а также некоторые тенденции и будущие перспективы в 
данной области. Представлено несколько последних разработок лабораторий Университета 
Северной Каролины и Московского государственного университета им. М.В. Ломоносова, 
включая высокомолекулярные полимерные мицеллы для одного и нескольких нерастворимых 
в воде лекарств. Обсуждаются наноразмерные полиионные комплексы, образованные 
ионными блок-сополимерами и полипептидами для доставки этих полипептидов. Примеры 
включают антиоксидантные ферменты (например, супероксиддисмутаза, каталаза), 
стехиометрические и каталитические поглотители фосфорорганических токсинов 
(бутирилхолинэстераза, органофосфатгидролаза) и нейротрофины (нейротрофический 
фактор мозга, нейротрофический фактор, полученный из глиальных клеток). Применение 
разработанных форм продемонстрировано на моделях животных и включает терапию 
ожирения, инсульта, болезни Паркинсона, синдрома Ретта, отравление фосфорорганическими 
токсинами и др. Представлено применение полиионных комплексов для доставки лекарств в 
макрофаги. В качестве примера изложена и проиллюстрирована концепция использования 
генетически модифицированных макрофагов в качестве естественных векторов доставки 
генов. Также обсуждена роль экзосом в доставке генов и белков и их потенциал в качестве 
нового фармацевтического подхода терапии.
Ключевые слова: наномедицина, доставка лекарственных средств, полимерные мицеллы, 
полиионные комплексы, носители лекарственных средств, экзосомы.
The purpose of this report is to briefly 
describe the current state of research in the field 
of “Nanomedicine and directed drug delivery”. 
No doubt, today it is a huge and rapidly 
developing field. The course of lectures I give 
for students and graduate students at the Faculty 
of Chemistry in Lomonosov Moscow State 
University is devoted to this research field. I am 
lucky enough to work in this field almost from 
the time it appeared since the end of the 1980s, 
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and together with Russian and international 
colleagues to carry out a number of studies that 
have influenced its development. In this regard, 
with the example of some of these studies, I will 
try to give my vision of the historical context 
and trends in the development of nanomedicine 
and drug delivery.
The nanomedicine approach is based on 
the use of nano-sized supramolecular particles 
as containers for the delivery of biologically 
active substances. By the end of the 80s, when 
we were just starting our work in this field, 
liposomes were actively studied and they were 
the first nanopreparations, applied in the clinic. 
Liposomes have an internal water reservoir, 
which is well used for the inclusion of hydrophilic 
substances delivered (for example, doxorubicin in 
the anticancer drug Doxil). However, with some 
exceptions, they are not very well suited for 
delivery of hydrophobic substances. The reason 
is that in the lipid bilayer, which is the basis of the 
vesicular structure of liposomes, there is usually 
not too much room for hydrophobic compounds 
to be included without a significant change in the 
structure of this bilayer.
A successful alternative for the inclusion 
of hydrophobic substances were micelles of 
amphiphilic block copolymers. In such micelles, 
insoluble polymer chains (blocks) form a 
hydrophobic core, and hydrophilic blocks create 
a water-soluble corona that retains micelles in 
the dissolved (dispersed) state. The polymer 
chains in the hydrophobic core of the micelle 
have sufficient “mobility” and can “make 
room” to include a significant amount of water-
insoluble drug compounds without significantly 
altering the overall structure of the micelle 
(core-corona). In the late 80-ies we carried out 
research in collaboration with V.P. Chekhonin 
and other colleagues and we used polymeric 
micelles for the brain-targeted delivery of 
non-covalently incorporated (“solubilized”) 
biologically active substances for the first time 
(Kabanov et al., 1989). Soon this field got a 
widespread development and was continued 
by the efforts of many laboratories, including 
ours, as well as prof. K. Kataoka in Japan and 
many others. Today, over a dozen of polymeric 
micelles-based drugs are in clinical trials and 
one drug developed in Korea, Genexol PM, has 
been approved for use in the treatment of breast, 
lung (NSCLC) and ovarian cancer.
In this regard, it should be mentioned that 
the world's first polymeric micelles-based drug, 
tested in the clinic was SP1049C, containing 
doxorubicin in micelles of poloxamers (also 
known as “Pluronic”), which we developed 
together with V.Yu. Alakhov and Supratek 
Pharma (Canada). The concept of this drug 
was based on the phenomenon of a significant 
increase in the sensitivity of cancer cells resistant 
to therapy under the influence of poloxamers 
(Pluronics) of a certain structure (Alakhov et 
al., 1996). We established the mechanisms of 
this phenomenon, including the interaction of 
poloxamers with membrane pumps and the 
mitochondrial respiratory chain (Batrakova et al., 
2001; Alakhova et al., 2010), and showed that this 
drug effectively kills not only multidrug-resistant 
tumors, but also tumor-initiating cells, and, on the 
whole, significantly increases the effectiveness of 
cancer treatment. Today, this drug successfully 
has passed the first and second phase of clinical 
trials for the treatment of upper gastrointestinal 
cancer and has reached the third phase.
Thus, polymeric micelles for drug delivery 
have become a reality in the clinic, and certainly, 
one should expect the market entry of many new 
drugs on this basis. New promising directions 
in this area include polymeric micelles of 
block copolymers of poly (2-oxazoline) with 
exceptionally high loading of hydrophobic drugs, 
reaching 50% of the weight of the micelle itself. 
For example, we recently created paclitaxel 
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preparations in which the drug's effective load 
exceed the drug content in Abraxan and Taxol, 
respectively, 10 and 100 times. Due to a sharp 
decrease in the content of polymer carriers and 
the possibility of increasing the concentration 
of the drug administered, the safe dose of the 
drug also significantly increases, which makes 
it possible to enhance the therapeutic effect (He 
et al., 2016). In animal models, the possibility 
of simultaneous administration of several 
chemotherapeutic drugs included in one micellar 
container is shown, which not only simplifies the 
practical application of combined chemotherapy 
“in one”, but also increases the effectiveness of 
these drugs by simultaneously delivering them to 
tumor cells.
Close to these studies are adjacent studies in 
the field of nano-gels and cross-linked polymeric 
micelles as drug delivery containers. We first 
used nano-gels from covalently linked polymer 
chains to deliver oligonucleotides, and then 
developed this approach for low molecular weight 
compounds, for example, cisplatin derivatives 
and combinations of these derivatives with 
other drugs (Vinogradov et al., 2002; Kabanov, 
Vinogradov, 2009).
By introducing chemical crosslinks 
between polymer chains the stability of the 
particle delivered in the body is achieved. By 
using bio-cleavable crosslinks it is possible to 
achieve controlled drug-release and destruction 
of the container at the end of its operation. Due 
to the stability of such a container in the body, 
it is possible to address it by antibodies or other 
biospecific molecules attached to the container 
(Nukolova et al., 2011, 2013).
An important role is played by the fact 
that nano-gels, swollen in water and polymeric 
micelles are poorly adsorbed on the surface of 
non-target cells, which improves the specificity 
of their delivery to target cells. In addition, by 
varying the number of cross-links it is possible to 
vary the swelling of nano-gels and their elasticity, 
which in principle can be used to improve their 
penetration into the tumor.
Returning to the origins of our work in the 
field of nanomedicine back into the late 80-ies in 
cooperation with V.A. Kabanov and V.I. Kiselev, 
we showed the possibility of packaging plasmid 
DNA by forming a polyelectrolyte DNA complex 
with polycations for the purpose of cell delivery 
(Kabanov et al., 1989, 1993). Such compact 
nanoscale complexes were subsequently called 
“polyplexes”, and they were prototypes of modern 
polycation – based cell transfection systems, 
which are now very widely used in laboratories. 
However, the limitation of such system was that 
to ensure the stability of polyplex nanoparticles 
in aqueous media it is necessary to add a large 
excess of polycation, which increases the toxicity 
of polyplexes, and, most importantly, makes it 
difficult to use them in a living organism due to 
the adsorption of seum proteins and aggregation 
of such particles in the blood.
The key solution was to use cationic block 
copolymers containing uncharged water-soluble 
chains such as, for example, polyethylene 
glycol (Kabanov et al., 1995). As a result, it 
became possible to obtain uncharged nanoscale 
polyelectrolyte micelles with a core of mutually 
neutralized nucleic acids and polycations and a 
corona of uncharged polymer chains. We called 
them “block-ionomer complexes” and carried 
out a wide range of research of the physical 
and chemical basis of formation, stability, and 
dynamic transformations of such complexes of 
various structures. From the point of view of 
nanomedicine and drug delivery, it is important 
that such particles are significantly less toxic and 
adsorb proteins to a far lesser extent. At present, 
they are being investigated by many laboratories 
for the development of directional delivery 
systems of nucleic acids in the body, including 
the tumor-targeted delivery of short interfering 
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RNA (research carried out at Moscow State 
University).
This approach turned out to be universal for 
the inclusion of not only nucleic acids, but also 
other biopolymers, in particular, proteins. Our 
works in this direction first focused on the creation 
of nanoscale complexes of enzymes, which we 
called “nanozymes”. Just as in the case of nucleic 
acids, such complexes are formed spontaneously 
when mixing the aqueous solutions of the protein 
and the corresponding block copolymer, in this 
case, either cationic or anionic, depending on 
the charge of the protein. The structure of the 
complexes is also characterized by the presence of 
a nucleus in which the enzyme molecules bound 
to the polyelectrolyte block and a hydrophilic 
corona formed from uncharged polymer chains 
are located. Crucially, the enzymes included in 
such structures retain the catalytic activity, and as 
a result nanozymes have the activity of the initial 
enzyme. A common thing for such systems is the 
significant stabilization of the proteins included 
in them, in particular, against proteolytic cleavage 
after the capture of nanozymes into cells, where 
the nanozymes remain active for hours and even 
days (Manickam et al., 2012).
One example of the use of the nanozyme 
approach was demonstrated by us at Moscow 
State University in the framework of the grant 
from the Government of the Russian Federation. 
In these studies we used a bacterial enzyme, 
organophosphate hydrolase, capable of cleavage 
of highly toxic organophosphate compounds used 
as pesticides and chemical warfare agents. This 
enzyme, obtained at the Department of Chemical 
Enzymology of Moscow State University is very 
active, however, its disadvantage is the relatively 
low stability and bacterial origin that makes it 
difficult to use in the body. We have shown that 
by including organophosphate hydrolase into a 
polyelectrolyte complex with a block copolymer 
of polyglutamic acid and polyethylene glycol, 
the stability of this enzyme can be significantly 
increased (the aqueous solution is stored without 
a significant change in activity up to two years), 
reduce the immune response, and increase the 
half-life when the enzyme is introduced into the 
body. Preparations of nanozyme organophosphate 
hydrolase with intravenous, intramuscular, and, 
in fact, buccal administration provide protection 
against multiple lethal doses of organophosphate 
pesticides and a warfare agent VX.
We also used this approach to create 
nanozymes based on antioxidant enzymes 
capable of cleaving toxic reactive oxygen species 
and thereby preventing tissue degeneration in 
various inflammatory processes. Stabilization of 
enzymes in nanozymes in combination with an 
increase of its circulation time and the ability to 
penetrate into the cells proved to be essential for 
improving the biological activity of the obtained 
nano-formulations. Thus, for example, superoxide 
dismutase 1 nanozymes were successfully used 
in animal models for neuroprotection in cerebral 
stroke, lowering blood pressure in heart failure 
and angiotensin II-stimulated hypertension, 
reducing inflammation of adipose tissue and aorta 
in obesity and in a number of other pathologies 
(Rosenbaugh et al., 2010; Jiang et al., 2015; 
Perriotte‐Olson et al., 2016).
The nanozyme preparation of superoxide 
dismutase 1 developed to in our laboratory at 
Moscow State University showed significant 
therapeutic activity in the treatment of inflammatory 
diseases of the eye and is now undergoing 
preclinical research with the support of the federal 
program “Development of the pharmaceutical and 
medical industry of the Russian Federation until 
2020” (Kost et al., 2016).
It should be noted that in addition to 
enzyme preparations, the described approach 
can be successfully applied for the delivery 
of polypeptides. In particular, we have shown 
the possibility of improving delivery of brain-
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derived neurotrophic factor (BDNF) to the 
brain. This hydrophobic and aggregation-
unstable polypeptide in aqueous solutions easily 
forms nanoscale stable complexes with a block 
copolymer of polyglutamic acid and polyethylene 
glycol. Moreover, these complexes are formed 
not only due to electrostatic, but also due to 
combinations of hydrophobic interactions and 
hydrogen bonds. Due to this, such complexes 
are unusually stable, but they easily rebuild and 
release neurotrophin upon interaction of the latter 
with the receptor (TrkB), whereby nano-BDNF 
is practically as active as the original protein. 
We have shown that the incorporation of BDNF 
into this complex significantly improves the 
delivery of this neurotrophin to the brain, both 
with intravenous and intranasal administration. 
Moreover, in studies of cerebral stroke in 
animal models, a significant improvement in 
the neuro-regenerative effect of BDNF has been 
demonstrated through the use of such nano-
formulation (Harris et al., 2016).
Many pathologies, in particular those 
related to brain diseases, are associated with 
the development of inflammatory processes 
during which infiltration of immune cells, 
including monocytes/macrophages, occurs 
that promote the oxidative stress of the leading 
degeneration of tissues. This occurs, for 
example, in Parkinson’s disease. We decided 
to use this circumstance to create a therapeutic 
approach, using the Trojan Horse principle. In 
this approach, the enzymes catalase nanozymes 
are loaded into macrophages in which they 
can exist for a very long time and from 
which are gradually released, while retaining 
catalytic activity. After introduction into the 
bloodstream of animals with an experimental 
model of Parkinson’s disease, such loaded 
macrophages accumulate in the area of disease 
and inflammation in the brain where the active 
nanozyme catalase is released and cleaves the 
hydrogen peroxide produced by macrophages. 
Thus, in animal models of Parkinson’s disease, 
a reduction in inflammation is achieved and a 
significant neuroprotective effect is observed, 
which is expressed in the preservation of 
dopaminergic neurons (Brynskikh et al., 2010).
The use of macrophages as drug delivery 
systems is counterintuitive for nanomedicine. In 
all the early works in this field, the task was to 
create such nanopreparations that would avoid 
capture by macrophages, acting as “cleaners” 
of the organism from alien objects. At the same 
time, already during the work on the mechanism 
of delivery of the “bare” plasmid DNA after its 
injection into the skeletal muscle, we noticed 
that in the phenomenon of a sharp increase 
in the expression of genes in the presence of 
poloxamers (Lemieux et al., 2000; Yang et al., 
2005) an important role is played by cells of the 
immune system and, first of all, macrophages. 
It turned out that when injected into the muscle 
with DNA, along with the poloxamer, which acts 
as a kind of “adjuvant” that activates the cells 
of the immune system, macrophages efficiently 
capture DNA, and not only transmit it to muscle 
cells, but can deliver it to distant organs from the 
injection site, in particular the lymph nodes and 
spleen (Gaymalov et al., 2009). It also turned 
out that the macrophages that captured DNA in 
the cell culture can “horizontally” transfer this 
DNA to cells of another type – muscles, neurons, 
cancer cells, while DNA is expressed in these 
new cells, even if it cannot be transcribed in the 
originally captured cells macrophages (Mahajan 
et al., 2016). Thus, transfected macrophages can 
act as “gene delivery systems” in other cells, 
including inflammation sites for various diseases. 
The principal possibility of this approach was 
demonstrated in models of Parkinson’s disease, 
when macrophages, trabsfected with catalase or 
glial cells derived neurotrophic factor (GDNF) 
were administered to animals. In both cases, the 
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macrophages administered into the bloodstream 
not only migrated to the brain, delivering the 
corresponding genes, but also ensured the 
effective expression of these genes, leading to 
significant neuroprotection (Haney et al., 2013; 
Zhao et al., 2014).
While studying the mechanisms of 
the transfer of nanosymes and DNA from 
macrophages to other cells we found that along 
with intercellular contacts, macrophages can 
also “repackage” the material contained in them 
and isolate it with the composition of exosomes – 
nanoscale extracellular vesicles. Exosomes 
contain many elements of the macrophage 
membrane and, like them, can accumulate 
in inflamed areas, particularly in the brain, 
transferring the material contained in them 
into new cells. Thus, modified exosomes can 
act as natural nanoparticles for drug delivery, 
and this new direction has recently been rapidly 
developing. In particular, the animal model has 
demonstrated the possibility of delivering a 
therapeutic protein included in exosomes into 
the brain to treat Parkinson’s disease (Haney et 
al., 2015).
In general, over the past quarter century 
in the field of nanomedicine and drug delivery 
new drugs have been introduced in the clinic 
and technologies have been developed to 
incorporate virtually any biologically active 
substances into biocompatible nanoscale 
containers. Moreover, it has become more 
understandable how these containers carry the 
included biologically active substances in the 
body and interact with healthy and diseased 
tissues. Approaches for non-invasive tracking 
of the processes of container transfer in the 
body have been developed. However, after the 
introduction of such containers into the body, we 
actually do not have the ability to control their 
function at the nanoscale, we cannot release 
medicines from them, turn them on or off at 
our discretion when they reach the target cells. 
Although this sounds almost fantastic today, the 
future development of science will undoubtedly 
go in this direction, and today we are already 
searching for fundamental opportunities 
for remote control of nano-drugs. One such 
possibility relates to the use of magnetic fields 
and superparamagnetic nanoparticles. While 
working in the framework of the grant of the 
Government of the Russian Federation in Moscow 
State University in cooperation with Tambov 
State University experimental installations for 
creating alternating magnetic fields of ultralow 
frequency have been developed and built. Such 
fields do not cause the heating of magnetic 
nanoparticles, but lead to their mechanical 
perturbation and the creation of a force that 
is transferred to the molecules of polymers 
attached to these particles. First, the possibility 
of a remote change in the rate of a biochemical 
reaction, catalyzed by an enzyme immobilized 
in a cluster of magnetic nanoparticles by an 
external non-heating alternating magnetic 
field was shown (Klyachko et al., 2012). It has 
also recently been established that within this 
“magneto-mechanical” approach, using an 
ultra-low frequency field of 50 Hz, it is possible 
to act on the cell from the inside, in particular, 
to destroy the cytoskeleton of cancer cells into 
which magnetic nanoparticles are preliminarily 
delivered (Master et al., 2016). Remarkably, 
the destruction of the cytoskeleton in normal 
epithelial cells does not occur, but occurs in 
cancerous cells because they have a less stable 
cytoskeleton.
Thus, the principle possibility of selective 
remote action on cancer cells with the help of 
external magnetic fields has been demonstrated. 
It is hoped that this and other similar approaches 
will be substantially developed in the nearest 
future and will lead to improving methods of 
diagnosing and treating human diseases.
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